New eye injection PRO-169 under safety review for Diabetes-Related vision loss
NCT ID NCT07429474
First seen Feb 26, 2026 · Last updated Jun 16, 2026 · Updated 10 times
Summary
This early-stage study tests whether PRO-169, an eye injection for diabetic macular edema, is safe by checking if the body creates antibodies against it. About 60 adults with diabetes will receive one injection, and researchers will monitor for immune reactions and side effects. The goal is to gather safety data, not to treat the condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETIC MACULAR EDEMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asociación para Evitar la Ceguera en México I.A.P
Coyoacán, Mexico City, 04030, Mexico
Contact
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.